Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 233.2M
Gross Profit 225.4M 96.68%
Operating Income -321.4M -137.83%
Net Income -321.5M -137.90%
EPS (Diluted) -$4.08

Balance Sheet Metrics

Total Assets 594.2M
Total Liabilities 535.0M
Shareholders Equity 59.1M
Debt to Equity 9.06

Cash Flow Metrics

Operating Cash Flow -194.1M
Free Cash Flow -338.7M

Revenue & Profitability Trend

Travere Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue233.2M145.2M109.5M131.8M198.3M
Cost of Goods Sold7.7M11.4M4.4M3.8M6.1M
Gross Profit225.4M133.8M105.0M128.0M192.2M
Operating Expenses546.8M510.5M424.9M327.4M271.2M
Operating Income-321.4M-376.7M-319.8M-199.4M-75.4M
Pre-tax Income-320.5M-376.1M-331.2M-216.9M-188.8M
Income Tax120.0K223.0K313.0K409.0K-19.4M
Net Income-321.5M-111.4M-278.5M-180.1M-169.4M
EPS (Diluted)-$4.08-$1.50-$4.37-$3.01-$3.56

Income Statement Trend

Travere Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets416.7M616.8M486.4M582.8M410.4M
Non-Current Assets177.5M172.2M186.2M193.8M197.0M
Total Assets594.2M789.0M672.6M776.6M607.4M
Liabilities
Current Liabilities200.8M177.9M142.2M124.1M92.7M
Non-Current Liabilities334.3M410.2M487.6M350.4M303.6M
Total Liabilities535.0M588.1M629.7M474.5M396.2M
Equity
Total Shareholders Equity59.1M200.8M42.9M302.1M211.2M

Balance Sheet Composition

Travere Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income-320.6M-376.3M-331.5M-217.3M-169.4M
Operating Cash Flow-194.1M-338.6M-285.7M-94.0M-45.4M
Investing Activities
Capital Expenditures--668.0K-191.0K-5.1M-6.8M
Investing Cash Flow200.5M-110.0M-4.2M-118.6M51.8M
Financing Activities
Dividends Paid-----
Financing Cash Flow132.6M189.1M112.5M222.8M121.8M
Free Cash Flow-338.7M-322.3M-214.8M-38.9M-162.6M

Cash Flow Trend

Travere Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -4.06
Forward P/E -13.39
Price to Book 44.14
Price to Sales 5.30
PEG Ratio -13.39

Profitability Ratios

Profit Margin -82.88%
Operating Margin -52.21%
Return on Equity -422.66%
Return on Assets -23.21%

Financial Health

Current Ratio 2.05
Debt to Equity 1,220.07
Beta 0.74

Per Share Data

EPS (TTM) -$2.78
Book Value per Share $0.37
Revenue per Share $3.35

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
tvtx1.5B-4.0644.14-422.66%-82.88%1,220.07
Vertex 114.1B32.826.92-5.64%-8.91%10.00
Regeneron 59.1B13.921.9715.96%31.94%9.20
Vera Therapeutics 1.6B-8.852.90-39.49%0.00%10.18
Immunocore Holdings 1.7B-33.904.41-5.86%-6.48%114.67
Agios 2.1B3.171.4460.26%1,798.26%3.61

Financial data is updated regularly. All figures are in the company's reporting currency.